Swing Therapeutics was founded in 2019 with the goal of developing digital treatments and services in disease areas where patients are not well-served, and where digital interventions may be effective. Its focus is on tackling autoimmune conditions and chronic overlapping pain conditions (COPCs) like fibromyalgia where central pain sensitization is a significant factor. The company is investing in research to support the development of prescription-based digital therapies and services. Swing Therapeutics received FDA Breakthrough Device Designation for its digital therapy for fibromyalgia management. Its near-term goal is to validate its digital therapy and bring it to market as an FDA-cleared, prescription digital therapeutic.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/16/22 | $10,300,000 | Series A |
Alumni Ventures Group AME Cloud Ventures Asahi Kasei Gaingels Jazz Venture Partners  Kicker Ventures Mana Ventures Metrodora Ventures | undisclosed |
